Elizabeth L. Christie
University of Melbourne
Serous fluidChemotherapyOvarian cancerCancer researchBiology
What is this?
Publications 23
#1Elizabeth H. Stover (Broad Institute)H-Index: 14
#2Maria B. Baco (Broad Institute)H-Index: 1
Last. Matthew Meyerson (Broad Institute)H-Index: 160
view all 29 authors...
High-grade serous ovarian cancer (HGSOC) is often sensitive to initial treatment with platinum and taxane combination chemotherapy, but most patients relapse with chemotherapy-resistant disease. To systematically identify genes modulating chemotherapy response, we performed pooled functional genomic screens in HGSOC cell lines treated with cisplatin, paclitaxel, or cisplatin plus paclitaxel. Genes in the intrinsic pathway of apoptosis were among the top candidate resistance genes in both gain-of...
1 CitationsSource
#1Emma Morrish (University of Melbourne)
#2Anthony Copeland (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 1
Last. Gabriela Brumatti (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 20
view all 19 authors...
Acute myeloid leukemia (AML) is an aggressive disease with a current 5-year survival rate of only ∼25%, therefore development of effective treatments towards resistant AML is urgently needed. Potential mechanisms of therapy resistance include overexpression of members of the inhibitor of apoptosis protein (IAP) family. Natural IAP antagonists such as second-mitochondria-derived activator of caspases (Smac) exist, leading to the pharmaceutical development of Smac-mimetics (SMs). The clinical SM b...
#1Elizabeth L. Christie (University of Melbourne)H-Index: 8
#2Swetansu Pattnaik (Garvan Institute of Medical Research)H-Index: 3
Last. David D.L. Bowtell (Garvan Institute of Medical Research)H-Index: 74
view all 15 authors...
ABCB1 encodes Multidrug Resistance protein (MDR1), an ATP-binding cassette member involved in the cellular efflux of chemotherapeutic drugs. Here we report that ovarian and breast samples from chemotherapy treated patients are positive for multiple transcriptional fusions involving ABCB1, placing it under the control of a strong promoter while leaving its open reading frame intact. We identified 15 different transcriptional fusion partners involving ABCB1, as well as patients with multiple disti...
3 CitationsSource
#1Lan G. Coffman (University of Pittsburgh)H-Index: 9
#2Alexander T. Pearson (UIC: University of Illinois at Chicago)H-Index: 11
Last. Ronald J. Buckanovich (University of Pittsburgh)H-Index: 27
view all 7 authors...
5 CitationsSource
#1Alison E. Freimund (University of Melbourne)H-Index: 2
#2Jessica A. Beach (Peter MacCallum Cancer Centre)H-Index: 2
Last. David D.L. Bowtell (University of Melbourne)H-Index: 74
view all 4 authors...
5 CitationsSource
#2Jessica A. BeachH-Index: 2
Last. David D.L. BowtellH-Index: 74
view all 10 authors...
#1Elizabeth L. Christie (Peter MacCallum Cancer Centre)H-Index: 8
#2Swetansu Pattnaik (Garvan Institute of Medical Research)H-Index: 3
Last. David D.L. Bowtell (Peter MacCallum Cancer Centre)H-Index: 74
view all 6 authors...
Acquired drug resistance is the major obstacle in controlling high-grade serous ovarian cancer (HGSC) and leads to poor overall survival. Comparatively little massively parallel sequencing data exist from HGSC patients with recurrent disease who have been extensively treated with chemotherapy or newer targeted agents, such as anti-angiogenics or PARP inhibitors (PARPi). We previously identified four mechanisms of acquired resistance from whole-genome sequencing (WGS) of 23 HGSC patients with rec...
#1Timothy O'Donnell (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 13
#2Elizabeth L. Christie (Peter MacCallum Cancer Centre)H-Index: 8
Last. Jeff Hammerbacher (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 10
view all 8 authors...
Background Patients with highly mutated tumors, such as melanoma or smoking-related lung cancer, have higher rates of response to immune checkpoint blockade therapy, perhaps due to increased neoantigen expression. Many chemotherapies including platinum compounds are known to be mutagenic, but the impact of standard treatment protocols on mutational burden and resulting neoantigen expression in most human cancers is unknown.
3 CitationsSource
#2Swetansu PattnaikH-Index: 3
Last. David D.L. BowtellH-Index: 74
view all 6 authors...
13 CitationsSource